| Product vision |
- Uncomplicated malaria treatment and resistance management
|
| MoA |
- Inhibition of Plasmodium falciparum Acyl-CoA synthetase 10/11
|
| Key features |
- Novel mode of action and structure
- Highly potent and active against resistant strains
- Fast killing in vitro and in vivo
- Low single dose prediction
|
| Challenges |
- Low potency on P. vivax and P. knowlesi malaria
- Limited solubility of crystalline material
|
| Status |
|
| Next milestone |
- Initiate first-in-human study
|
| Previously |
- Discovery by GSK with support from the Wellcome Trust
- Full reference name is MMV1582367
|
| MMV Project Director |
|
